These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

111 related articles for article (PubMed ID: 2281090)

  • 1. Migration of immunomodulated cultured lymphocytes in malignant tumors.
    McAfee JG
    Prog Clin Biol Res; 1990; 355():105-14. PubMed ID: 2281090
    [No Abstract]   [Full Text] [Related]  

  • 2. Natural killer cells and tumor immunity: 1987.
    Hiserodt JC; Herberman RB
    Year Immunol; 1989; 4():201-7. PubMed ID: 2648702
    [No Abstract]   [Full Text] [Related]  

  • 3. Tumor-infiltrating lymphocytes: evidence for specific immune reactions against growing cancers in mice and humans.
    Topalian SL; Rosenberg SA
    Important Adv Oncol; 1990; ():19-41. PubMed ID: 2182519
    [No Abstract]   [Full Text] [Related]  

  • 4. Ex vivo activation and retransfusion of white blood cells. The immunotherapy of cancer.
    Hamblin TJ
    Curr Stud Hematol Blood Transfus; 1990; (57):249-66. PubMed ID: 2272205
    [No Abstract]   [Full Text] [Related]  

  • 5. Interleukin 2 in cancer therapy.
    Testa U; Montesoro E; Bulgarini D; Samoggia P; Masciulli R; Habetswallner D; Carè A; Mariani G; Giannella G; Boccoli G
    Ann Ist Super Sanita; 1990; 26(3-4):283-334. PubMed ID: 2091501
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Augmentation of therapeutic effect of adoptive immunotherapy through a synergy between transferred killer cells and host's fresh lymphocytes].
    Kan N; Yamasaki S; Harada T; Satoh K; Ichinose Y; Moriguchi Y; Kodama H; Ohgaki K
    Hum Cell; 1992 Sep; 5(3):236-42. PubMed ID: 1467322
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [A new approach to immunotherapy of cancer based on autologous T-lymphocytes].
    Dosne Pasqualini C; Laguens RP
    Medicina (B Aires); 1987; 47(3):307-12. PubMed ID: 3326997
    [No Abstract]   [Full Text] [Related]  

  • 8. Adoptive immunotherapy with recombinant interleukin 2, LAK and TIL.
    Kurnick JT; Kradin RL
    Allergol Immunopathol (Madr); 1991; 19(5):209-14. PubMed ID: 1811418
    [No Abstract]   [Full Text] [Related]  

  • 9. "Lymphokine activated killing" as treatment for human cancer: clinical extrapolations from laboratory studies with interleukin-2 expanded leukocytes.
    Sondel PM; Hank JA; Kohler PC; Chen BP; Sosman J
    Prog Clin Biol Res; 1989; 288():151-60. PubMed ID: 2654949
    [No Abstract]   [Full Text] [Related]  

  • 10. [Experimental and clinical study of adoptive immunotherapy combined with preadministration of OK-432: a method to augment the therapeutic effect].
    Kan N; Okino T; Nakanishi M; Sato K; Mise K; Teramura Y; Yamasaki S; Hori T; Ohgaki K; Tobe T
    Gan To Kagaku Ryoho; 1989 Apr; 16(4 Pt 2-2):1455-61. PubMed ID: 2786379
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Tumor-infiltrating lymphocytes from human solid tumors: antigen-specific killer T lymphocytes of activated natural killer lymphocytes.
    Whiteside TL; Heo DS; Takagi S; Herberman RB
    Immunol Ser; 1989; 48():139-57. PubMed ID: 2488318
    [No Abstract]   [Full Text] [Related]  

  • 12. Natural killer cells.
    Herberman RB
    Prog Clin Biol Res; 1989; 288():161-7. PubMed ID: 2470107
    [No Abstract]   [Full Text] [Related]  

  • 13. Immunological effects of adoptive immunotherapy with IL-2: an overview.
    Kradin R; Yamin R; Kurnick J
    Pathol Immunopathol Res; 1988; 7(6):434-41. PubMed ID: 3070529
    [No Abstract]   [Full Text] [Related]  

  • 14. Cancer treatment by photodynamic therapy combined with adoptive immunotherapy using genetically altered natural killer cell line.
    Korbelik M; Sun J
    Int J Cancer; 2001 Jul; 93(2):269-74. PubMed ID: 11410876
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Endogenous and adoptively transferred A-NK and T-LAK cells continuously accumulate within murine metastases up to 48 h after inoculation.
    Hokland M; Kjaergaard J; Kuppen PJ; Nannmark U; Agger R; Hokland P; Basse P
    In Vivo; 1999; 13(3):199-204. PubMed ID: 10459491
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cancer immunotherapy using interleukin-2 and interleukin-2-activated lymphocytes.
    Rosenberg SA; Lotze MT
    Annu Rev Immunol; 1986; 4():681-709. PubMed ID: 3518753
    [No Abstract]   [Full Text] [Related]  

  • 17. [Studies on lymphokine-activated killer (LAK) cell: accumulation in tumor tissue and the therapeutic effects of adoptive immunotherapy].
    Wakizaka Y
    Hokkaido Igaku Zasshi; 1992 Jul; 67(4):475-87. PubMed ID: 1330859
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Potential uses of interleukin 2 in cancer therapy.
    Cheever MA; Thompson JA; Peace DJ; Greenberg PD
    Immunobiology; 1986 Sep; 172(3-5):365-82. PubMed ID: 3492434
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Interleukin-2: its rationale and role in the treatment of patients with cancer.
    Rubin JT
    Cancer Treat Res; 1995; 80():83-105. PubMed ID: 8821575
    [No Abstract]   [Full Text] [Related]  

  • 20. Adoptive immunotherapy in the treatment of malignant disease.
    Klein HG; Leitman SF
    Transfusion; 1989 Feb; 29(2):170-8. PubMed ID: 2645696
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 6.